Neurodegenerative Diseases Market - Global Professional Analysis and Forecast to 2026

Mar 30, 2020 | 180 PAGES | REPORT CODE: CMM274522

REPORT SUMMARY
TABLE OF CONTENTS
INDUSTRY COVERAGE

The worldwide Neurodegenerative Diseases market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.1% during the forecast period.

This report presents the market size and development trends by detailing the Neurodegenerative Diseases market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Neurodegenerative Diseases market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Neurodegenerative Diseases industry and will help you to build a panoramic view of the industrial development.

Neurodegenerative Diseases Market, By Type:

NMDA
SSRIs
Dopamine Inhibitors

Neurodegenerative Diseases Market, By Application:

Parkinson’s disease
Huntington disease
Amyotrophic Lateral Sclerosis
Alzheimer’s disease

Some of the leading players are as follows:

Novartis
Eisai
Alector
Teva Pharmaceutical
Pfizer
Biogen Idec
Bayer Schering Pharma AG
UCB
Addex Pharmaceutical
Asubio Pharmaceutical
Amarin
AstraZeneca
Jiangsu Hansoh Pharmaceutical
Bial
Merck Serono
Boehringer Ingelheim
Yangtze River Pharmaceutical Group
Yumanity Therapeutics
Chongqing Zein Pharmaceutical

Geographically, Major regions are analyzed in details are as follows:

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Table of Contents

1 Methodology and Scope

1.1 Market Segmentation & Scope

1.1.1 Technology Type
1.1.2 Product
1.1.3 Application
1.1.4 Regional scope
1.1.5 Estimates and forecast timeline

1.2 Research Methodology
1.3 Information Procurement

1.3.1 Purchased database
1.3.2 Internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research

1.4 Information or Data Analysis

1.4.1 Data analysis models

1.5 Market Formulation & Validation
1.6 Model Details

1.6.1 Commodity flow analysis
1.6.2 Volume price analysis

1.7 List of Secondary Sources
1.8 List of Abbreviations

2 Executive Summary

2.1 Market Outlook
2.2 Segment Outlook

3 Market Variables, Trends, & Scope

3.1 Market Lineage Outlook
3.1.1 Parent market outlook

3.1.2 Ancillary market outlook

3.2 Market Segmentation

3.2.1 Analysis

3.3 Market Dynamics

3.3.1 Market driver analysis
3.3.2 Market restraint analysis
3.3.3 Industry opportunities

3.4 Penetration & Growth Prospect Mapping

3.4.1 Penetration & growth prospect mapping analysis

3.5 Business Environment Analysis Tools

3.5.1 Porter's five forces analysis
3.5.2 PESTLE analysis
3.5.3 Major deals & strategic alliances analysis

4 Neurodegenerative Diseases Market: Technology Type Analysis

4.1 Neurodegenerative Diseases Technology Type Market Share Analysis, 2018 & 2026
4.2 Neurodegenerative Diseases Technology Type Market: Segment Dashboard
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

4.3.1 NMDA
4.3.2 SSRIs
4.3.3 Dopamine Inhibitors

5 Neurodegenerative Diseases Market: Product Analysis

5.1 Neurodegenerative Diseases Product Market Share Analysis, 2018 & 2026
5.2 Neurodegenerative Diseases Product Market: Segment Dashboard
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Neurodegenerative Diseases Market: Application Analysis

6.1 Neurodegenerative Diseases Application Market Share Analysis, 2018 & 2026
6.2 Neurodegenerative Diseases Application Market: Segment Dashboard
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

6.3.1 Parkinson’s disease
6.3.2 Huntington disease
6.3.3 Amyotrophic Lateral Sclerosis
6.3.4 Alzheimer’s disease

7 Neurodegenerative Diseases Market: Regional Analysis

7.1 Neurodegenerative Diseases Regional Market Share Analysis, 2018 & 2026
7.2 Neurodegenerative Diseases Regional Market: Segment Dashboard
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
7.4 List of Players at Regional Level

7.4.1 North America
7.4.2 Europe
7.4.3 Asia Pacific

7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA

7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

7.6.1 North America
7.6.2 Europe
7.6.3 Asia Pacific
7.6.4 Latin America
7.6.5 Middle East & Africa

8 Competitive Analysis

8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
8.3 Vendor Landscape

8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

9.1 Novartis

9.1.1 Novartis Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis

9.2 Eisai

9.2.1 Eisai Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis

9.3 Alector

9.3.1 Alector Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis

9.4 Teva Pharmaceutical

9.4.1 Teva Pharmaceutical Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis

9.5 Pfizer

9.5.1 Pfizer Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis

9.6 Biogen Idec

9.6.1 Biogen Idec Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis

9.7 Bayer Schering Pharma AG

9.7.1 Bayer Schering Pharma AG Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis

9.8 UCB

9.8.1 UCB Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis

9.9 Addex Pharmaceutical

9.9.1 Addex Pharmaceutical Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis

9.10 Asubio Pharmaceutical

9.10.1 Asubio Pharmaceutical Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis

9.11 Amarin

9.11.1 Amarin Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis

9.12 AstraZeneca

9.12.1 AstraZeneca Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis

9.13 Jiangsu Hansoh Pharmaceutical

9.13.1 Jiangsu Hansoh Pharmaceutical Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis

9.14 Bial

9.14.1 Bial Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis

9.15 Merck Serono

9.15.1 Merck Serono Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis

9.16 Boehringer Ingelheim

9.16.1 Boehringer Ingelheim Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis

9.17 Yangtze River Pharmaceutical Group

9.17.1 Yangtze River Pharmaceutical Group Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.17.5 SWOT analysis

9.18 Yumanity Therapeutics

9.18.1 Yumanity Therapeutics Company overview
9.18.2 Financial performance
9.18.3 Product benchmarking
9.18.4 Strategic initiatives
9.18.5 SWOT analysis

9.19 Chongqing Zein Pharmaceutical

9.19.1 Chongqing Zein Pharmaceutical Company overview
9.19.2 Financial performance
9.19.3 Product benchmarking
9.19.4 Strategic initiatives
9.19.5 SWOT analysis

The List of Tables and Figures (Totals 111 Figures and 125 Tables)

Figure NMDA Neurodegenerative Diseases market, 2015 - 2026 (USD Million)
Figure SSRIs Neurodegenerative Diseases market, 2015 - 2026 (USD Million)
Figure Dopamine Inhibitors Neurodegenerative Diseases market, 2015 - 2026 (USD Million)
Figure Parkinson’s disease market, 2015 - 2026 (USD Million)
Figure Huntington disease market, 2015 - 2026 (USD Million)
Figure Amyotrophic Lateral Sclerosis market, 2015 - 2026 (USD Million)
Figure Alzheimer’s disease market, 2015 - 2026 (USD Million)
Table List of players in North America
Table List of players in Europe
Table List of players in Asia Pacific
Table SWOT analysis
Table North America Neurodegenerative Diseases market, by country, 2015 - 2026 (USD Million)
Table North America Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table North America Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table North America Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table U.S. Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table U.S. Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table U.S. Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table Canada Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Canada Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Canada Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Europe Neurodegenerative Diseases market, by country, 2015 - 2026 (USD Million)
Table Europe Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Europe Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Europe Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table U.K. Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table U.K. Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table U.K. Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table Germany Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Germany Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Germany Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table France Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table France Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table France Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table Italy Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Italy Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Italy Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table Spain Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Spain Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Spain Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Asia Pacific Neurodegenerative Diseases market, by country, 2015 - 2026 (USD Million)
Table Asia Pacific Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Asia Pacific Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Asia Pacific Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table China Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table China Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table China Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table Japan Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Japan Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Japan Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table India Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table India Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table India Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Latin America Neurodegenerative Diseases market, by country, 2015 - 2026 (USD Million)
Table Latin America Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Latin America Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Latin America Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table Brazil Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Brazil Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Brazil Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table Mexico Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Mexico Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Mexico Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table Argentina Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Argentina Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Argentina Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table MEA Neurodegenerative Diseases market, by country, 2015 - 2026 (USD Million)
Table MEA Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table MEA Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table MEA Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table South Africa Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table South Africa Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table South Africa Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Regulatory scenario
Table Nigeria Neurodegenerative Diseases market, by type, 2015 - 2026 (USD Million)
Table Nigeria Neurodegenerative Diseases market, by product, 2015 - 2026 (USD Million)
Table Nigeria Neurodegenerative Diseases market, by application, 2015 - 2026 (USD Million)
Table Recent Developments & Impact Analysis, by Key Market Participants
Table Recent Developments & Impact Analysis, by Key Market Participants
Table Company market position analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Eisai Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Alector Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Teva Pharmaceutical Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Biogen Idec Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bayer Schering Pharma AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table UCB Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Addex Pharmaceutical Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Asubio Pharmaceutical Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Amarin Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Jiangsu Hansoh Pharmaceutical Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bial Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck Serono Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Yangtze River Pharmaceutical Group Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Yumanity Therapeutics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Chongqing Zein Pharmaceutical Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis

REPORTS

Let’s Pullulate and Expand Your Business

Neurodegenerative Diseases Market - Global Professional Analysis and Forecast to 2026

Report Purchase